Description
Background: Initial opioid prescribing for acute pain contributes substantially to opioid exposure and can drive persistent use, increasing the risk of overdose and opioid use disorder. Most U.S. states have implemented opioid prescribing limits (OPLs) to restrict initial opioid prescription duration, quantity, or dosage. However their intended and unintended impacts remain poorly understood. This narrative review summarizes evidence from U.S. studies evaluating the impact of OPLs on prescribing, patient, and public health outcomes, while identifying gaps and priorities for future research. Methods: We reviewed U.S. studies published between April 2016 and January 2026 evaluating statutory OPLs. Literature was identified through searches of PubMed, Web of Science, and Embase. We considered observational studies examining OPL effects among opioid-naive and commonly exempt populations (e.g., chronic pain), reporting outcomes related to prescribing patterns, patient health, opioid-related adverse events, or patient-reported outcomes. Studies assessing system-level interventions or prescription drug monitoring programs were not considered, nor were commentaries or reviews. Findings were organized into key themes across literature. Result: The literature on OPLs has evolved beyond prescribing metrics, where reductions in days supply, quantity dispensed, and morphine milligram equivalents (MMEs) are consistently observed, to a broader consideration of patient and public health outcomes. Studies in postoperative populations show similar declines in initial prescribing. Research links OPLs to reductions in opioid related hospitalizations and emergency department visits, with limited literature suggesting decreases in synthetic opioid overdose deaths. Similarly, spillover effects were reported among patients with chronic pain or cancer. A small body of literature suggests potential clinician workaround, reflected in increases in new fills, follow-up prescriptions, and per-capita MME exposure over time. Corroborating this, qualitative findings describe clinicians‚ defensive prescribing practices, where shorter initial prescriptions prompt repeated refills, leaving unused medications at home and increasing the risks of diversion. Evidence on substitution to benzodiazepines or non opioid therapies remains sparse and inconclusive, and no studies have examined transitions to illicit opioid use. Conclusion: Current evidence indicates that state opioid prescribing limits reduce initial opioid supply but offers mixed evidence on broader patient and public health outcomes. Further research is needed to clarify these impacts to inform
Publication Info
2026.